Compare · ARGX vs CMPX
ARGX vs CMPX
Side-by-side comparison of argenx SE (ARGX) and Compass Therapeutics Inc. (CMPX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and CMPX operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $52.52B, about 325.2x CMPX ($161.5M).
- Over the past year, ARGX is down 2.8% and CMPX is down 79.6% - ARGX leads by 76.8 points.
- Both names hit the wire about 6 times in the past 4 weeks.
- Both have 25 recent analyst ratings on file.
- Company
- argenx SE
- Compass Therapeutics Inc.
- Price
- $819.19-3.28%
- $0.87-3.00%
- Market cap
- $52.52B
- $161.5M
- 1M return
- -17.73%
- -53.32%
- 1Y return
- -2.77%
- -79.57%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 6
- 6
- Recent ratings
- 25
- 25
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Compass Therapeutics Inc.
Compass Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing antibody therapeutics to treat solid tumors and hematologic malignancies. The company is leveraging its proprietary StitchMabs and common light-chain enabled multi specific platforms to identify multi specifics and combinations of antibody therapeutics that could be advanced to the clinic. Its lead product candidate is CTX-471, a monoclonal antibody agonist of CD137, a co-stimulatory receptor on immune cells that is being evaluated in a Phase 1 study in patients who were previously treated with PD-1/PD-L1 checkpoint inhibitors and who subsequently relapsed or progressed after a period of stable disease. The company is also developing CTX-8371, a bispecific antibody that targets PD-1 and PD-L1. In addition, it is developing a portfolio of bispecific and monoclonal antibody product candidates, which are in preclinical development. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Latest ARGX
- argenx to Report Third Quarter 2026 Financial Results and Business Update on October 22, 2026
- SEC Form 6-K filed by argenx SE
- argenx Provides Update on Phase 3 UNITY Study of Efgartigimod SC in Sjögren's Disease
- argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease
- SEC Form 6-K filed by argenx SE
- argenx Presents New Data at AANEM and MGFA Scientific Session Showcasing Earlier and Sustained Treatment in MG and CIDP with VYVGART and Progress Across its Neuromuscular Pipeline
- argenx announces results of Extraordinary General Meeting of Shareholders and appointment of Thomas M. Brakel and Khurem Farooq as Non-Executive Directors
- argenx to Present at Upcoming Investor Conferences
- SEC Form 6-K filed by argenx SE
- Amendment: SEC Form SC TO-T/A filed by argenx SE
Latest CMPX
- Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Chief Accounting Officer Lerner Neil bought $18,400 worth of shares (20,000 units at $0.92), increasing direct ownership by 5% to 420,000 units (SEC Form 4)
- Chief Accounting Officer Lerner Neil bought $2,850 worth of shares (2,500 units at $1.14), increasing direct ownership by 0.63% to 400,000 units (SEC Form 4)
- Compass Therapeutics downgraded by Wedbush with a new price target
- Compass Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA Feedback
- SEC Form SCHEDULE 13G filed by Compass Therapeutics Inc.
- SEC Form 10-Q filed by Compass Therapeutics Inc.
- Compass Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update